Become a partner

Status update on ATMP membership

2024-03-26

Föreningen ATMP Sweden elects a new board

Föreningen ATMP Sweden (fATMP Sweden) is the non profit member organisation that was formed in 2023 to support continuation of the ATMP Sweden communication and coordination platforms. fATMP Sweden has been busy this last year setting up the governance structures of the the non profit in order to not only accept members but to take legal ownership of the ATMP Sweden communication platforms, including the atmpsweden.se website, the ATMP world tour and the ATMP Sweden annual conference.

Since starting to accept members in November 2023, close to 100 individuals and organisations have already joined, members from Sweden and International. Here are some quotes from our inaugural members!

”I joined ATMP Sweden because medicines based on genes, cells or tissue engineering is a rapidly evolving area. With a solid background in regulatory affairs, I am convinced that sharing of knowledge as well as early and regular dialogue with the regulators are keys aspect to successfully bring these new treatments to patients”, Margareth Jorvid, Regulatory Affairs & Quality Assurance Methra Uppsala AB. Senior Partner of LSM group.

”Being part of the ATMP Sweden ecosystem is crucial for a company like CombiGene AB. When you are pioneering new technologies like we do, you need access to knowledge and experience in order to succeed and ATMP Sweden provides just that”, Jan Nilsson, Senior Executive Advisor at CombiGene.

”Many ATMPs are directed towards “difficult-to-treat” diseases, this includes many cancers, rare and genetic diseases. The Swedish Childhood Cancer Fund recognises the importance of this field and of our need to raise the patient’s perspective in the development of these medicines. Through out ATMP Sweden membership we hope to contribute to a faster access to safe and effective innovative therapies for patients who need it the most.” Associate Professor Kerstin Sollerbrant, The Swedish Childhood Cancer Fund, Patient representative in EMAs Committee for Advanced Therapies.

”I have joined ATMP Sweden as I am interested in following the development of advanced therapies at universities and companies in Sweden that lead to clinical studies and are the basis for future marketing approvals. I hope for interesting discussions in this national network!” says Lennart Åkerblom,  Former Pharmaceutical assessor at Swedish Medical Products Agency/Läkemedelsverket.

The 2024 AGM elected a new Board, including Agneta Edberg (Chair), Jukka Lausmaa (Treasurer), Gisela Helenius (Secretary), Anders Lindahl (Deputy secretary), Alexandra Karström, Dag Larsson, Kerstin Sollebrant, Lilian Walther Jallow and Åse Rosenqvist. The board consists of a balanced mix of individuals with different expertises and perspectives in ATMP, including communication, business and financing, national collaboration, translation from the academic lab to the clinic, SMEs and big pharma, policies, and clinical practice.

Read more about the benefits of being an ATMP Sweden member and how to sign up!